We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-10.62%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.76B
AUM Growth
-$25.9M
Cap. Flow
+$49.6M
Cap. Flow %
1.8%
Top 10 Hldgs %
58.38%
Holding
114
New
31
Increased
18
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
C icon
Citigroup
C
+$14.9M
2
DG icon
Dollar General
DG
+$14.5M
3
MJN
Mead Johnson Nutrition Company
MJN
+$12.2M
4
APTV icon
Aptiv
APTV
+$9.58M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.21M

Top Sells

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$11.8M
2
GS icon
Goldman Sachs
GS
+$8.41M
3
CCI icon
Crown Castle
CCI
+$7.34M
4
XOMA
Xoma
XOMA
+$7.26M
5
FURX
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
+$5.55M

Sector Composition

Rank Sector Weight
1 Miscellaneous 52.76%
2 Consumer Discretionary 22.6%
3 Healthcare 22.19%
4 Consumer Staples 1.28%
5 Financials 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
76
Ionis Pharmaceuticals
IONS
$8.55B
$4.32M 0.16%
+100,000
New +$4.85M
AGIO icon
77
Agios Pharmaceuticals
AGIO
$2.01B
$3.92M 0.14%
100,000
-10,000
-9% -$335K
MTOR
78
DELISTED
MERITOR, Inc.
MTOR
$3.67M 0.13%
300,000
-350,000
-54% -$3.93M
CMCSK
79
DELISTED
COMCAST CORP SPL A (NEW)
CMCSK
$3.66M 0.13%
+75,000
New +$3.66M
NKTR icon
80
CALL
Nektar Therapeutics
NKTR
$2.34B
$3.64M 0.13%
+20,000
New +$3.96M
BLUE
81
DELISTED
bluebird bio
BLUE
$3.41M 0.12%
11,580
– –
SPHS
82
DELISTED
Sophiris Bio, Inc.
SPHS
$3.33M 0.12%
1,000,000
– –
AVNR
83
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$3.3M 0.12%
900,000
-1,100,000
-55% -$4.19M
STML
84
DELISTED
Stemline Therapeutics, Inc.
STML
$3.16M 0.11%
155,000
-15,000
-9% -$364K
IRWD icon
85
Ironwood Pharmaceuticals
IRWD
$689M
$2.67M 0.1%
258,954
– –
RXDX
86
DELISTED
Ignyta, Inc.
RXDX
$2.49M 0.09%
+300,000
New +$2.81M
AMBI
87
DELISTED
Ambit Biosciences Corp
AMBI
$2.28M 0.08%
250,000
– –
CPAC
88
Cementos Pacasmayo
CPAC
$1.07B
$2.25M 0.08%
205,580
-40,747
-17% -$499K
NEOG icon
89
Neogen
NEOG
$2.61B
$2.25M 0.08%
+133,333
New +$2.18M
TEX icon
90
Terex
TEX
$6.95B
$2.21M 0.08%
+50,000
New +$2.1M
CSLT
91
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$2.12M 0.08%
+100,000
New +$2.9M
CCXI
92
DELISTED
ChemoCentryx, Inc.
CCXI
$1.82M 0.07%
275,000
– –
AGEN
93
Agenus
AGEN
$312M
$1.3M 0.05%
20,896
– –
AMRN
94
CALL
Amarin Corp
AMRN
$291M
$905K 0.03%
25,000
-25,000
-50% -$929K
AAPL icon
95
CALL
Apple
AAPL
$4.86T
– –
-2,800,000
Closed -$56.1M
CCI icon
96
Crown Castle
CCI
$31.6B
– –
-100,000
Closed -$7.34M
COF icon
97
CALL
Capital One
COF
$127B
– –
-400,000
Closed -$30.6M
F icon
98
CALL
Ford
F
$55.3B
– –
-1,300,000
Closed -$20.1M
GDX icon
99
CALL
VanEck Gold Miners ETF
GDX
$28.3B
– –
-200,000
Closed -$4.23M
GS icon
100
Goldman Sachs
GS
$288B
– –
-50,000
Closed -$8.41M
1 2 3
4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2014 Portfolio in Review

As of Q1 2014, Artal Group held 114 positions worth $2.76B, down 0.93% from $2.79B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Artal Group's Q1 2014 filing shows 31 new, 18 increased, 24 reduced and 20 closed positions. Its largest new stake was Citigroup: 300,000 shares worth $14.3M. The largest sale was Acorda Therapeutics, an estimated $11.8M.

By sector, the portfolio is most concentrated in Miscellaneous at 53% of assets, up from 42% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Artal Group's largest Q1 2014 buy was Citigroup: 300,000 shares worth $14.3M.
  • Artal Group added most to BioMarin Pharmaceuticals in Q1 2014, an estimated $9.21M increase.
  • Artal Group's biggest Q1 2014 reduction was Acorda Therapeutics, cutting an estimated $11.8M.
  • Artal Group fully exited Goldman Sachs in Q1 2014, selling an estimated $8.41M.
  • Artal Group's ten largest holdings make up 58% of its $2.76B portfolio in Q1 2014.
  • Artal Group opened 31 new positions and closed 20 in Q1 2014.
  • Artal Group's portfolio value fell 0.93% quarter-over-quarter to $2.76B.

Based on Artal Group's 13F filing for Q1 2014, filed 15 May 2014.